Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED CONFERENCE CALL TO DISCUSS FIRST HALF OF FISCAL YEAR 2013 RESULTS
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced it will
hold a conference call to discuss its results for the first half of its fiscal year 2013, the period from July 1 through December 31, 2012. The half year report was previously released on the 28th of February 2013 and is available through the Investor Relations
section of the Company s website at www.primabiomed.com.au.
The call is scheduled for Thursday, the 7th of March 2013 at 9:00am (Sydney local time). Conference call dial-in
numbers are as follows:
| Australia Toll Free | 1 800 131 617 | |||
| Australia Alternate Toll Free | 1 800 838 758 | |||
| USA & Canada | 1 855 237 2970 | |||
| Germany | 0800 189 9369 |
The call will also be audio webcast with additional supplemental slides available via
http://services.choruscall.com/links/primabiomed130306.html. Before launching the webcast, it is recommended to click on the link and then on test your systems configuration.
A replay of the teleconference and webcast will be available through Prima s website following the live event.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging
its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian
cancer patients who are in remission.
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
2 9276 1224 Fax: +61 2 9276 1284
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
(0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284